(Q31044135)

28 June 2017

0 references

1 reference

title

Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence (English)

1 reference

28 June 2017

0 references

1 reference

Carlo Di Pietrantonj

3

0 references

Tom Jefferson

series ordinal

1

object named as

Tom Jefferson

1 reference

28 June 2017

Melanie Rudin

2

1 reference

28 June 2017

publication date

1 February 2004

1 reference

Lancet Infectious Diseases

28 June 2017

published in

1 reference

28 June 2017

volume

4

1 reference

28 June 2017

issue

2

1 reference

28 June 2017

page(s)

84-90

1 reference

Aluminum salts in vaccines--US perspective

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Macrophagic myofasciitis: a summary of Dr. Gherardi's presentations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

The global impact of vaccines containing aluminium adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Overview of vaccine adjuvants: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Systematic review of the effects of pertussis vaccines in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Advantages of Aluminium Hydroxide Adsorbed Combined Diphtheria, Tetanus, and Pertussis Vaccines for the Immunization of Infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

The role of aluminium for adverse reactions and immunogenicity of diphtheria-tetanus booster vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants--II

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Symptoms after primary immunisation with DTP and with DT vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900927-2

7 January 2021

10.1016/S1473-3099(04)00927-2

Identifiers

DOI

1 reference

28 June 2017

1 reference